Giving another chance to mifepristone in pharmacotherapy of aggressive meningiomas. A likely synergism with hydroxyurea?

High grade meningiomas (HGM) are relatively rare, yet their fatal course constitutes a significant health problem. Pharmacological options include hydroxyurea (HU), somatostatin and IFN-alpha. HU inhibits ribonucleotide reductase subunit 2 (RRM2) and thereby DNA synthesis and its dose-limiting toxicity is myelosuppression. During embryogenesis, RRM2 is specifically induced by progesterone in uterine implantation sites. Meningioma growth is stimulated with pregnancy and exogenous progesterone analogues.

Source: Current Problems in Cancer - May 15, 2016 Category: Cancer & Oncology Authors: İlhan Elmacı, Meric A. Altinoz, Aydin Sav, Zeliha Yazici, Aysel Ozpinar Source Type: research